When Chris Viehbacher was running Sanofi ($SNY), he had a plan to cut costs in France, in part by shuttering an R&D site in Toulouse that he said was so bad it hadn't developed an important drug in 20 years. Viehbacher was fired in October, and now Sanofi plans to pay German company Evotec at least €250 million ($310 million) over 5 years to take over the operations there and see if it can shift drug discovery into a higher gear. Story from FierceBiotech | More